NCT00232973Unknown3 期
A Prospective, Multi-Centre, Double Blind, Randomized, Placebo Controlled Trial to Evaluate the Safety and Efficacy of ICXP007 in a Phase III Trial With Four-Layer Therapeutic Compression, for the Treatment of Non-Infected Skin Leg Ulcers, Due to Venous-Insufficiency
Intercytex114 个研究点 分布在 3 个国家目标入组 396 人开始时间: 2005年7月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 396
- 试验地点
- 114
- 主要终点
- Incidence of 100% closure (epithelialized) at any time during the initial 12 weeks of the treatment period.
研究概览
简要总结
The main purpose of the study is to compare treatment of non-infected venous leg ulcers using ICXP007 combined with four-layer compression bandaging, placebo combined with four-layer compression bandaging and four-layer compression bandaging alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Individuals who have a graft-ready venous leg ulcer of at least 3 months duration, which has not, responded to standard conventional therapy.
- •Individuals who have an Ankle Brachial Pressure Index (ABPI/ABI) of greater than or equal to 0.8 measured by Doppler sonography.
- •Individuals who have venous incompetency as defined by > 1.0 seconds in vein segments on standing reflux exam by duplex or an abnormal venous refill time of < 21 seconds by PPG or > 2 cc per second by APG. Duplex or PPG/APG will be used to establish venous insufficiency. Doppler will be utilized to rule out arterial disease.
- •Individuals who have a target wound which is between 2 cm2 to 20 cm2 in area at the screening assessment.
- •Individuals who are ambulatory.
- •Individuals who have voluntarily signed and dated a patient IRB/EC approved Informed Consent Form (ICF).
- •Individuals, who are, in the opinion of the Investigator, able to understand this study, co-operate with the study procedures and are willing to return to the clinic for all the required follow-up visits.
排除标准
- •Individuals with a known hypersensitivity to Aprotinin or any other constituents of Tisseel VH S/DTM i.e. Fibrinogen (human), thrombin (human) and Calcium Chloride, Bovine and Porcine products.
- •Individuals who have a haemoglobin or serum albumin level which is < 10 g/dL or < 2.5 g/dL respectively, or is otherwise outside the normal range and deemed clinically significant.
- •Females who are pregnant, lactating, or who have not reached menopause and are not abstinent or practicing an acceptable means of birth control as determined by the Investigator for the duration of the study.
- •Individuals younger than 18 years of age.
- •Individuals with abnormal blood biochemistry defined as 3 times that of the upper limit of the normal range and/or any other abnormal laboratory finding considered clinically significant.
- •Individuals who have exposed bone, tendon or fascia visible around the target wound.
- •Individuals with evidence of collagen vascular diseases, such as vasculitis or rheumatoid arthritis, under active treatment.
- •Individuals with evidence of cellulitis or osteomyelitis during the previous 4 weeks.
- •Individuals who have a target wound which shows signs of clinical infection or who have a wound that has presence of ß-haemolytic streptococcus upon culture, or the Investigator suspects may be severely infected. Individuals may be enrolled upon eradication of the ß-haemolytic streptococcus infection/organism.
- •Individuals who have any clinically significant medical condition that would impair wound healing as determined by the Investigator, including uncontrolled diabetes as determined by HbA1C (>12%), or immune disease.
- •Individuals who are known to abuse alcohol or drugs currently, or to have psychological disorders that could affect follow-up care or treatment outcomes.
- •Individuals who have chronic renal insufficiency requiring haemodialysis.
- •Individuals who have received short course corticosteroids within 30 days, or oral or parenteral chronic immunosupressants within 90 days prior to treatment.
- •Individuals who have, or are suspected of having malignancy, or who have received treatment for any active malignancy, apart from non-melanomatic skin cancer, within 3 months prior to treatment.
- •Individuals who have participated in a clinical study of any investigational product within 2 months prior to treatment.
- •Individuals who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.
- •Individuals previously enrolled/randomized in this clinical trial.
结局指标
主要结局
Incidence of 100% closure (epithelialized) at any time during the initial 12 weeks of the treatment period.
时间窗: 12 weeks
次要结局
- Time to first closure.
- Percentage of Day 0 wound surface area.
- Overall rate of wound area reduction during treatment.
- Percentage reduction in wound surface area from previous visit.
- Percentage reduction in wound surface area from Day 0.
- Appearance of new ulcer in the target wound area post closure.
- Incidence of closure at 16, 20 and 24 weeks.
- Incidence of reopening at up to 16, 20 and 24 weeks.
- Incidence of re-closure at 16, 20 and 24 weeks.
- Qualitative levels of wound pain.
研究者
研究点 (114)
Loading locations...
相似试验
已完成
3 期
Pivotal Trial of Dermagraft(R) to Treat Venous Leg UlcersVenous Leg UlcerNCT00909870Organogenesis537
已完成
2 期
A Study to Investigate the Efficacy, Safety and Tolerability of Nexagon® as a Topical Treatment for Subjects With Venous Leg UlcersVenous Leg UlcersNCT01199588OcuNexus Therapeutics, Inc.300
招募中
不适用
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.WoundsWound of SkinWound LegVenous Leg UlcerFoot WoundDiabetic Foot UlcerNCT05588583Molnlycke Health Care AB68
Enrolling By Invitation
不适用
Comparison of Human Allograft to Apligraf for Venous Leg UlcersVenous Leg UlcersNCT02047084Solsys Medical LLC50
招募中
不适用
A Clinical Investigation to Follow the Progress of Exuding Chronic Venous Leg Ulcers Using a Non-Bordered Foam DressingWoundsWound of SkinWound LegVenous Leg UlcerNCT05608317Molnlycke Health Care AB20